Medication adherence and cognitive performance in schizophrenia-spectrum and bipolar disorder: results from the PsyCourse Study
Standard
Medication adherence and cognitive performance in schizophrenia-spectrum and bipolar disorder: results from the PsyCourse Study. / Senner, Fanny; Hiendl, Lena; Bengesser, Susanne; Adorjan, Kristina; Anghelescu, Ion-George; Baune, Bernhardt T; Budde, Monika; Dannlowski, Udo; Dietrich, Detlef E; Falkai, Peter; Fallgatter, Andreas J; Hasan, Alkomiet; Heilbronner, Maria; Jäger, Markus; Juckel, Georg; Kalman, Janos L; Konrad, Carsten; Kohshour, Mojtaba Oraki; Papiol, Sergi; Reich-Erkelenz, Daniela; Reimer, Jens; Schaupp, Sabrina K; Schmauß, Max; Senner, Simon; Spitzer, Carsten; Vogl, Thomas; Zimmermann, Jörg; Heilbronner, Urs; Schulte, Eva C; Schulze, Thomas G; Reininghaus, Eva Z; Kirchner, Sophie-Kathrin; Dalkner, Nina.
In: TRANSL PSYCHIAT, Vol. 13, No. 1, 25.03.2023, p. 99.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Medication adherence and cognitive performance in schizophrenia-spectrum and bipolar disorder: results from the PsyCourse Study
AU - Senner, Fanny
AU - Hiendl, Lena
AU - Bengesser, Susanne
AU - Adorjan, Kristina
AU - Anghelescu, Ion-George
AU - Baune, Bernhardt T
AU - Budde, Monika
AU - Dannlowski, Udo
AU - Dietrich, Detlef E
AU - Falkai, Peter
AU - Fallgatter, Andreas J
AU - Hasan, Alkomiet
AU - Heilbronner, Maria
AU - Jäger, Markus
AU - Juckel, Georg
AU - Kalman, Janos L
AU - Konrad, Carsten
AU - Kohshour, Mojtaba Oraki
AU - Papiol, Sergi
AU - Reich-Erkelenz, Daniela
AU - Reimer, Jens
AU - Schaupp, Sabrina K
AU - Schmauß, Max
AU - Senner, Simon
AU - Spitzer, Carsten
AU - Vogl, Thomas
AU - Zimmermann, Jörg
AU - Heilbronner, Urs
AU - Schulte, Eva C
AU - Schulze, Thomas G
AU - Reininghaus, Eva Z
AU - Kirchner, Sophie-Kathrin
AU - Dalkner, Nina
N1 - © 2023. The Author(s).
PY - 2023/3/25
Y1 - 2023/3/25
N2 - Existing guidelines recommend psychopharmacological treatment for the management of schizophrenia and bipolar disorder as part of holistic treatment concepts. About half of the patients do not take their medication regularly, although treatment adherence can prevent exacerbations and re-hospitalizations. To date, the relationship between medication adherence and cognitive performance is understudied. Therefore, this study investigated the relationship between medication adherence and cognitive performance by analyzing the data of 862 participants with schizophrenia-spectrum and bipolar disorders (mean [SD] age, 41.9 [12.48] years; 44.8% female) from a multicenter study (PsyCourse Study). Z-scores for three cognitive domains were calculated, global functioning was measured with the Global Assessment of Functioning Scale, and adherence was assessed by a self-rating questionnaire. We evaluated four multiple linear regression models and built three clusters with hierarchical cluster analyses. Higher adherence behavior (p < 0.001) was associated with better global functioning but showed no impact on the cognitive domains learning and memory, executive function, and psychomotor speed. The hierarchical cluster analysis resulted in three clusters with different cognitive performances, but patients in all clusters showed similar adherence behavior. The study identified cognitive subgroups independent of diagnoses, but no differences were found in the adherence behavior of the patients in these new clusters. In summary, medication adherence was associated with global but not cognitive functioning in patients with schizophrenia-spectrum and bipolar disorders. In both diagnostic groups, cognitive function might be influenced by various factors but not medication adherence.
AB - Existing guidelines recommend psychopharmacological treatment for the management of schizophrenia and bipolar disorder as part of holistic treatment concepts. About half of the patients do not take their medication regularly, although treatment adherence can prevent exacerbations and re-hospitalizations. To date, the relationship between medication adherence and cognitive performance is understudied. Therefore, this study investigated the relationship between medication adherence and cognitive performance by analyzing the data of 862 participants with schizophrenia-spectrum and bipolar disorders (mean [SD] age, 41.9 [12.48] years; 44.8% female) from a multicenter study (PsyCourse Study). Z-scores for three cognitive domains were calculated, global functioning was measured with the Global Assessment of Functioning Scale, and adherence was assessed by a self-rating questionnaire. We evaluated four multiple linear regression models and built three clusters with hierarchical cluster analyses. Higher adherence behavior (p < 0.001) was associated with better global functioning but showed no impact on the cognitive domains learning and memory, executive function, and psychomotor speed. The hierarchical cluster analysis resulted in three clusters with different cognitive performances, but patients in all clusters showed similar adherence behavior. The study identified cognitive subgroups independent of diagnoses, but no differences were found in the adherence behavior of the patients in these new clusters. In summary, medication adherence was associated with global but not cognitive functioning in patients with schizophrenia-spectrum and bipolar disorders. In both diagnostic groups, cognitive function might be influenced by various factors but not medication adherence.
KW - Humans
KW - Female
KW - Adult
KW - Male
KW - Schizophrenia/drug therapy
KW - Bipolar Disorder/diagnosis
KW - Executive Function
KW - Cognition
KW - Multivariate Analysis
KW - Neuropsychological Tests
U2 - 10.1038/s41398-023-02373-x
DO - 10.1038/s41398-023-02373-x
M3 - SCORING: Journal article
C2 - 36966169
VL - 13
SP - 99
JO - TRANSL PSYCHIAT
JF - TRANSL PSYCHIAT
SN - 2158-3188
IS - 1
ER -
